Abstract
This is an excellent time for patients with hepatitis C virus infection who have failed past treatment with standard of care (SOC) peginterferon (PEG-IFN) and ribavirin (RBV). New treatments have been shown to increase sustained virological response (SVR) rates. Previous relapsers and those with some responsiveness to interferon will clearly benefit from protease inhibitor-based therapy. Patients with little interferon response may not be suited for these regimens, but can be treated by careful selection on a case-by-case basis. Resistance needs to be carefully monitored as these newer and more potent drugs are added to IFN and RBV backbone drugs. Adverse events will be more frequent and will require special attention.
© 2012 John Wiley & Sons A/S.
MeSH terms
-
Anemia / chemically induced
-
Anemia / therapy
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Clinical Trials, Phase III as Topic*
-
Drug Substitution
-
Drug Therapy, Combination
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon-alpha / adverse effects
-
Interferon-alpha / therapeutic use*
-
Oligopeptides / adverse effects
-
Oligopeptides / therapeutic use
-
Polyethylene Glycols / adverse effects
-
Polyethylene Glycols / therapeutic use*
-
Proline / adverse effects
-
Proline / analogs & derivatives*
-
Proline / therapeutic use
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Recurrence
-
Ribavirin / adverse effects*
-
Ribavirin / therapeutic use
-
Serine Proteinase Inhibitors / therapeutic use*
-
Skin Diseases / chemically induced
-
Standard of Care
-
Treatment Failure
Substances
-
Antiviral Agents
-
Interferon-alpha
-
Oligopeptides
-
Recombinant Proteins
-
Serine Proteinase Inhibitors
-
Polyethylene Glycols
-
Ribavirin
-
telaprevir
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Proline
-
peginterferon alfa-2a